Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115664) titled 'Efficacy and Safety of QL1706 Combined with Anlotinib in Patients with Advanced Esophageal Squamous Cell Carcinoma Who Failed First-Line Immunotherapy: A Prospective, Single-Arm, Phase II Clinical Study' on Dec. 30, 2025.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The Affiliated Hospital of Qingdao University
Condition:
Esophageal squamous cell carcinoma
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-01-05
Target Sample Size: Experimental Group:37;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?...